FDA approved GAMMAGARD LIQUID ERC for use, while EMA had already approved it as DEQSIGA. The company also benefited from market trends.
2 reports, 1 independent
Updated Jul 15
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved GAMMAGARD LIQUID ERC for use, while EMA had already approved it as DEQSIGA. The company also benefited from market trends.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.
- Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.
- FDA review extended for ruxolitinib cream, while Incyte benefits from potential Trump-era tariffs, leading to analyst upgrades and recommendations.
- IGC Pharma, Inc. is preparing data for potential U.S. FDA review and seeking EMA support for its lead drug candidate.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
Coverage
Newest first; wire copies grouped- Insider MonkeyTakeda Pharmaceutical (TAK) Gets GAMMAGARD LIQUID ERC Approved by FDA Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the 13 Best Japanese Stocks to Buy According to Hedge Funds. On June 3
- Unknown outlet